The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

Bicycle modifications can potentially improve genitourinary outcomes after cycling. For example, in our cohort, cyclists who stood more than 20% of the time while cycling and adjusted the handlebar to ...

Key Takeaways Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T ...

On July 10, 2024, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2025 Medicare Physician Fee Schedule Proposed Rule. It outlines CMS’ proposed updates for payments ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

In this interview, Arpeet Shah, MD, considers some of the advancements and challenges that the field of urology will face in the coming year. Shah is a urologist at Associated Urological Specialists, ...

Panelists discuss the specific PD-1/PD-L1 inhibitors currently being investigated in phase 3 trials for BCG-naive patients with non–muscle-invasive bladder cancer (NMIBC), including CREST, POTOMAC, ...

Video content above is prompted by the following: Please review different treatment delivery options available for management of NMIBC. It is an exciting time for NMIBC, as several delivery systems ...

Key Takeaways Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed ...